Pirttikangas C O, Perttilä J, Salo M
Department of Anaesthesiology, University of Turku, Finland.
Intensive Care Med. 1993;19(5):299-302. doi: 10.1007/BF01690552.
To test propofol lipid emulsion formulation for its immunosuppressive effects.
Propofol lipid emulsion and the emulsion alone were tested at increasing concentrations and compared to initial values and between each other. Propofol alone could not be tested due to its insolubility into the culture medium.
Lymphocytes from 12 surgical intensive care (ICU) patients (median APACHE score 16 and median TISS score 28) and 12 healthy volunteers.
Phytohaemagglutinin-, concanavalin A- and pokeweed mitogen-induced lymphocyte proliferative responses were measured in the presence of increasing concentrations of propofol lipid emulsion formulation or the lipid emulsion.
Lymphocyte proliferative responses from ICU patients were in general on a lower level than in the volunteers. The propofol lipid emulsion formulation (Diprivan) decreased pokeweed mitogen-induced proliferative responses of lymphocytes from ICU patients at propofol concentrations found in the circulation (1-10 micrograms/ml) and the lipid emulsion alon at 100 micrograms/ml triglyceride concentrations while the other mitogen-induced responses were not affected. No changes were observed in the mitogen-induced responses of lymphocytes from healthy volunteers.
Propofol emulsion formulation decreased in surgical intensive care patients pokeweed mitogen-induced lymphocytic responses in vitro at clinically found concentrations, indicating the need for further studies to test B-lymphocyte functions and T-B-lymphocyte co-operation during propofol lipid emulsion administration. (ICU) patients is widespread because of its good control of sedation. Propofol is currently administered in fat emulsion which is considered immunosuppressive during bolus injection or rapid infusion. Therefore, effects of a propofol fat emulsion formulation on proliferative responses of lymphocytes were studied in blood samples obtained from healthy volunteers and ICU patients known to be immunosuppressed.
测试丙泊酚脂质乳剂配方的免疫抑制作用。
对丙泊酚脂质乳剂及单纯乳剂进行不同浓度测试，并与初始值及彼此之间进行比较。由于丙泊酚在培养基中不溶，无法单独对其进行测试。
12名外科重症监护病房（ICU）患者（急性生理与慢性健康状况评分系统[APACHE]中位数为16，治疗干预评分系统[TISS]中位数为28）的淋巴细胞以及12名健康志愿者的淋巴细胞。
在丙泊酚脂质乳剂配方或脂质乳剂浓度不断增加的情况下，测量植物血凝素、刀豆蛋白A和商陆有丝分裂原诱导的淋巴细胞增殖反应。
ICU患者的淋巴细胞增殖反应总体上低于志愿者。丙泊酚脂质乳剂配方（得普利麻）在循环中发现的丙泊酚浓度（1 - 10微克/毫升）时，降低了ICU患者淋巴细胞对商陆有丝分裂原诱导的增殖反应，而在甘油三酯浓度为100微克/毫升时，单纯脂质乳剂也有此作用，而其他有丝分裂原诱导的反应未受影响。健康志愿者淋巴细胞的有丝分裂原诱导反应未观察到变化。
在临床发现的浓度下，丙泊酚乳剂配方降低了外科重症监护患者体外商陆有丝分裂原诱导的淋巴细胞反应，这表明需要进一步研究以测试丙泊酚脂质乳剂给药期间B淋巴细胞功能和T - B淋巴细胞协作情况。由于其对镇静的良好控制，丙泊酚在ICU患者中的应用很广泛。丙泊酚目前以脂肪乳剂形式给药，在大剂量注射或快速输注期间被认为具有免疫抑制作用。因此，在从已知免疫抑制的健康志愿者和ICU患者获取的血样中，研究了丙泊酚脂肪乳剂配方对淋巴细胞增殖反应的影响。
